Bidirectional Effects of Endogenous Opioid Peptides on Endothelin Release Rates in Porcine Aortic Endothelial Cell Culture: Mediation by Delta Opioid Receptor and Opioid Receptor Antagonist-insensitive Mechanisms
Overview
Affiliations
The effects of opioid peptides on immunoreactive endothelin (ir ET) release from cultured porcine aortic endothelial cells over a 1-hr period (4-5 or 23-24 hr) were determined by radioimmunoassay and high-performance liquid chromatography after treatment for either 4 or 23 hr. Endogenous opioids, the synthetic delta opioid [D-Pen2,5]enkephalin and, for comparison, atrial and brain natriuretic peptides were added to the culture medium in concentrations ranging from 10(-12) to 10(-7) M. Thrombin (0.1-10 U/ml) served as a stimulatory reference. 1) Brain natriuretic peptide displayed only insignificant effects on ir ET release at 5 hr, but strongly inhibited ir ET release at 24 hr. 2) Opioids modulated release rates at 5 hr but did not display significant effects at 24 hr: metorphamide with predominant mu/kappa and weak delta opioid receptor activity stimulated release in a dose-dependent manner, whereas [Met5]enkephalin-Arg6-Phe7 with mu/delta activity and the delta agonists [Leu5]enkephalin, sulfated [Leu5]enkephalin and [D-Pen2,5]enkephalin decreased release rates; [Leu5]enkephalin was the most potent of the latter drugs. 3) Coincubation with either the nonselective opioid receptor antagonist naloxone (10(-5) M) or the delta receptor-selective antagonist ICI-174,864 (N,N-bisallyl-Tyr-D-Ala-Aib-Aib-Phe-Leu-OH) (10(-5) M) abolished all opioid-induced inhibitory effects, but rather potentiated or unmasked stimulatory effects of opioid peptides on ir ET release rates at 5 hr and also at 24 hr in the case of the delta agonists.(ABSTRACT TRUNCATED AT 250 WORDS)
Zhang R, Chen M, Deng Z, Kong L, Shen B, Zhang L Pharmaceutics. 2023; 15(1).
PMID: 36678674 PMC: 9861451. DOI: 10.3390/pharmaceutics15010046.
Short S, Wilkinson K, Long D, Judd S, Schulte J, Kissela B J Stroke Cerebrovasc Dis. 2021; 31(2):106237.
PMID: 34896817 PMC: 8792292. DOI: 10.1016/j.jstrokecerebrovasdis.2021.106237.
Dynorphins in Development and Disease: Implications for Cardiovascular Disease.
Cissom C, Paris J, Shariat-Madar Z Curr Mol Med. 2019; 20(4):259-274.
PMID: 31746302 PMC: 7457512. DOI: 10.2174/1566524019666191028122559.
Pourshanazari A, Allahtavakoli M, Hassanshahi G Iran J Basic Med Sci. 2013; 14(6):560-7.
PMID: 23493527 PMC: 3586858.
Perivascular expression and potent vasoconstrictor effect of dynorphin A in cerebral arteries.
Ruisanchez E, Cselenyak A, Papp R, Nemeth T, Kaldi K, Sandor P PLoS One. 2012; 7(5):e37798.
PMID: 22662226 PMC: 3360594. DOI: 10.1371/journal.pone.0037798.